Business · 15/11/1994Updated: 10/18/2026 · 1 min read
FDA Determines Regulatory Review Period for Patent Extension of CPI Ventak PRx AICD System
Summary
The Food and Drug Administration has officially set a regulatory review period for the patent extension of CPI Ventak PRx AICD System, following a submission to the US Patent and Trademark Office, as required by law.
Original source language: Federal Register — Health and Human ServicesOpen original release →